Brief: Inhibikase Therapeutics Provides Interim Update On '501' Bioequivalence Study Of IkT-001Pro
15/03/2023 12:57
March 15 (Reuters) - Inhibikase Therapeutics Inc
IKT.O :
* INHIBIKASE THERAPEUTICS PROVIDES INTERIM UPDATE ON THE
'501'
BIOEQUIVALENCE STUDY OF IKT-001PRO
* INHIBIKASE THERAPEUTICS INC - COMPLETED DOSING OF 3 OF 4
PLANNED
COHORTS; EXPECT TO COMPLETE STUDY IN Q2 OF 2023
* INHIBIKASE THERAPEUTICS - FOLLOWING COMPLETION OF 501
TRIAL,
PLANS TO INITIATE A DISCUSSION WITH FDA ON PARAMETERS FOR
APPROVAL OF IKT-001PRO
* INHIBIKASE THERAPEUTICS INC - ON TRACK TO COMPLETE 501
TRIAL IN
Q2 OF 2023
Source text for Eikon: ID:nPn1NzFMha
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share